Tagrisso's Second Act: The Combo Bet That Could Rewrite Lung Cancer Resistance
AstraZeneca's Tagrisso just got a powerful sidekick. The Phase III SAFFRON trial showed that adding Hutchmed's Orpathys extended survival in lung cancer patients whose tumors outsmarted first-line treatment, and the implications stretch far beyond one clinical readout.
Cancer's Favorite Escape Route Just Got Blocked
Imagine you change the locks on your front door, but the burglar starts climbing through the window. That's basically what happens in EGFR-mutated lung cancer when patients take AstraZeneca's blockbuster drug Tagrisso.
Tagrisso (osimertinib) works brilliantly at first. It blocks a specific protein called EGFR that drives tumor growth. But cancer is resourceful. In roughly one in five patients, the tumor finds a workaround: it amplifies a different protein called MET, essentially opening a side door that lets the cancer keep growing. Doctors call this MET-driven resistance, and until now, the playbook for treating it has been murky at best.
That changed this week. Results from the Phase III SAFFRON trial showed that combining Tagrisso with Hutchmed's Orpathys (savolitinib) significantly extended both progression-free survival and overall survival compared to standard platinum chemotherapy. For the first time, there's Phase III evidence that you can lock the front door and board up the window at the same time.
What SAFFRON Actually Showed
The trial enrolled 338 patients worldwide whose EGFR-mutated lung cancer had progressed on Tagrisso and whose tumors showed high MET overexpression or amplification. Half got Orpathys (300 mg twice daily) plus Tagrisso (80 mg once daily). The other half got the old fallback: platinum-based doublet chemotherapy.
Both co-primary endpoints hit. Patients on the combo lived longer without their cancer worsening (PFS) and lived longer overall (OS), with both results reaching statistical significance. AstraZeneca hasn't released the exact median survival numbers yet, but the signal was described as "clinically meaningful," which in pharma-speak means it wasn't just a technicality on a stats table.
This wasn't a surprise out of nowhere, either. Two earlier trials laid the groundwork. The Phase II SAVANNAH study had already shown a and in a similar biomarker-selected population. And the Phase III trial, which tested the combo across a broader set of MET-amplified patients, reported a median PFS of versus for chemotherapy. SACHI's overall survival numbers (22.9 months versus 17.7 months) were trending positive but weren't mature enough to be definitive.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
56% response rate
7.4-month median PFS
SACHI
8.2 months
4.5 months
SAFFRON, by delivering both PFS and OS, closes the loop.
Why This Is Really About Tagrisso's Future
Let's zoom out from the clinical data for a second, because the business story here might matter even more.
Tagrisso is one of AstraZeneca's crown jewels. It's approved in more than 100 countries as a standalone therapy. But like every blockbuster drug, it faces a looming patent cliff. AstraZeneca's strategy for protecting the franchise isn't subtle: make Tagrisso the backbone of EGFR-mutated lung cancer treatment across every disease stage, then layer on combinations that keep patients in the AstraZeneca ecosystem even after resistance kicks in.
Think of it like a streaming service. Tagrisso is the flagship show that gets you to subscribe. The combinations (Orpathys for MET resistance, Datroway for other progression scenarios, chemo from the FLAURA2 data) are the spin-offs designed to keep you from canceling. FLAURA2 already showed that adding chemotherapy to Tagrisso upfront pushed median overall survival to 47.5 months, compared to 37.6 months for Tagrisso alone. Now SAFFRON adds another chapter for patients whose cancer finds a way around the original treatment.
For AstraZeneca, every month a patient stays on a Tagrisso-based regimen is another month of revenue before generics arrive.
The MET Resistance Problem Is Bigger Than One Drug
MET amplification isn't some rare curiosity. Depending on the study, it shows up in roughly 5% to 22% of EGFR-mutated lung cancer patients after their tumors stop responding to EGFR-targeted therapy. It's consistently ranked as one of the most common acquired resistance mechanisms. And despite that prevalence, there hasn't been a validated standard second-line regimen specifically designed for these patients.
The typical approach has been to run molecular profiling on a tumor biopsy after progression, confirm that MET is the culprit, and then cobble together a treatment plan. Sometimes that meant a clinical trial. Sometimes it meant chemotherapy, which works but comes with well-known toxicity tradeoffs. The field has lacked a clean, biomarker-directed, all-oral option backed by Phase III survival data.
SAFFRON fills that gap. An oral pill combo, selected by a specific biomarker, that beats chemo on survival. That's the kind of result that changes treatment guidelines.
What It Means for Hutchmed
Hutchmed has been quietly building Orpathys into a real asset, particularly in China. The drug received full approval from China's NMPA in January 2025 for MET exon 14 skipping-mutated lung cancer, covering both treatment-naïve and previously treated patients. Then in June 2025, China approved the Orpathys plus Tagrisso combination specifically for EGFR-mutated lung cancer with MET amplification after EGFR-TKI progression.
That June approval triggered an $11 million milestone payment from AstraZeneca to Hutchmed and opened the door for national reimbursement coverage negotiations in China. Orpathys had already been on China's National Reimbursement Drug List (NRDL) since March 2023 for its earlier indication.
The partnership between AstraZeneca and Hutchmed dates back to 2011, when the two companies struck a global licensing and collaboration agreement. Under this arrangement, AstraZeneca is responsible for commercialization worldwide, while HUTCHMED leads joint development in China and AstraZeneca leads development outside China. HUTCHMED is also responsible for marketing authorization, manufacturing, and supply in China. If SAFFRON's data support regulatory submissions in the U.S., Europe, and other major markets, the economics of this deal could look very different in the next 12 to 18 months.
The Caveats Worth Watching
No trial result comes without asterisks. First, while SAFFRON confirmed statistical significance on both endpoints, the exact survival numbers haven't been publicly disclosed yet. The full data presentation (likely at a major oncology conference) will determine how enthusiastically the field embraces this combo. A few extra months of survival is meaningful but different from a transformative leap.
Second, this is a biomarker-selected population. Not every patient who progresses on Tagrisso has MET-driven resistance, and the testing infrastructure needed to identify eligible patients (tumor biopsies, MET amplification assays) adds complexity. Broader adoption depends on how easily oncologists can identify the right patients in real-world practice.
Finally, combination tolerability matters. The safety profile has looked manageable in earlier studies, but real-world use across diverse patient populations will be the ultimate test.
The Bottom Line
For years, MET-driven resistance after Tagrisso was a well-understood problem without a well-proven solution. SAFFRON changes that equation. It gives AstraZeneca a survival-backed combination to extend Tagrisso's franchise, gives Hutchmed a global regulatory catalyst for Orpathys, and most importantly, gives patients with a specific, testable form of drug resistance a targeted oral therapy that outperforms chemotherapy.
The data aren't perfect (we're still waiting on the actual numbers), but the direction is clear. Cancer found a window; this combo just nailed it shut.
Funding & Financings
5 min read
CSL Just Had Its Best Day in 25 Years. Here's What Lit the Fuse.
CSL posted a $2.6 billion net loss and its stock soared 18%, the best single-day move in 25 years. Behind the apparent contradiction lies a "reset year" ending, a massive buyback, and a plasma market where demand keeps outrunning supply.
